secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0000950170-25-102447
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Corbus Pharmaceuticals Q2 2025 Net Loss $17.7M, Pipeline on Track for Data Readouts H2 2025
--------------------------------------------------------------------------------

- Net loss for Q2 2025 was $17.7 million ($1.44 per share), compared to $10.0 million loss in Q2 2024.
- Cash and investments totaled $116.6 million as of June 30, 2025, expected to fund operations through Q2 2027.
- Phase 1/2 dose expansion data for Nectin-4 ADC CRB-701 to be presented at ESMO 2025 in October.
- Obesity drug CRB-913 initiated multiple ascending dose portion; SAD/MAD data expected later in 2025.
- FDA granted Fast Track designation for CRB-701 in relapsed/refractory metastatic cervical cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017025102447/0000950170-25-102447-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017025102447/crbp-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-102447

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer